CD13 Antigens (Alanine Aminopeptidase)

Zinc-binding metalloproteases that are members of the type II integral membrane metalloproteases. They are expressed by GRANULOCYTES; MONOCYTES; and their precursors as well as by various non-hematopoietic cells. They release an N-terminal amino acid from a peptide, amide or arylamide.

Also Known As:

Networked: 425 relevant articles (7 outcomes, 40 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Xu, Wenfang: 23 articles (08/2013 - 01/2005)
2.	Fang, Hao: 13 articles (06/2013 - 05/2007)
3.	Reinhold, Dirk: 11 articles (01/2012 - 01/2006)
4.	Bank, Ute: 10 articles (01/2012 - 01/2006)
5.	Ansorge, Siegfried: 10 articles (01/2012 - 01/2006)
6.	Lendeckel, Uwe: 10 articles (01/2010 - 12/2003)
7.	Corti, Angelo: 9 articles (12/2013 - 11/2003)
8.	Ponzoni, Mirco: 7 articles (08/2015 - 11/2003)
9.	Wang, Xuejian: 7 articles (10/2012 - 12/2008)
10.	Täger, Michael: 7 articles (01/2012 - 01/2006)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2013 - "Aminopeptidase N (APN) inhibitors have been reported to be effective in treating of life threatening diseases including cancer. " 01/15/2004 - "We have shown previously that targeted delivery of TNF to aminopeptidase N (CD13), a marker of angiogenic vessels, improved the therapeutic index of this cytokine in tumor-bearing mice. " 01/20/2004 - "In present study, PsA was found to inhibit mammalian aminopeptidase N (APN) that plays a key role in tumor cell invasion and angiogenesis. " 12/01/2015 - "Aminopeptidase N (APN, also known as CD13) is involved in cellular processes of various types of tumors and a potential anti-cancer therapeutic target. " 07/01/2015 - "Aminopeptidase N (APN/CD13) is involved in tumor cell invasion and tumor angiogenesis and is considered a promising therapeutic target in the treatment of cancer. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/15/2005 - "The aim of this study was to evaluate the clinical significance of circulating aminopeptidase N/CD13 protein detected by mAb MH8-11 in patients with non-small cell lung cancer (NSCLC). " 01/01/2015 - "Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer." 11/01/2009 - "Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer." 07/01/2006 - "Clinical significance of aminopeptidase N in non-small cell lung cancer." 12/15/2005 - "Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer."
3.	Leukemia 01/01/2010 - "Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells." 04/28/2006 - "A mutation in aminopeptidase N (CD13) isolated from a patient suffering from leukemia leads to an arrest in the endoplasmic reticulum." 10/01/2004 - "Most of them had the morphological changes such as the leukemia cells' indent nucleus with a light stain region of perinucleus, basophilic cytoplasm, differentiation with maturation, megaloblastoid changes and nuclear-cytoplasm imbalance; the high expression of CD13 antigen; and the AML1/ETO fusion transcript in 23 cases examined by reverse transcription-polymerase chain reaction (RT-PCR) assay, including 6 cases with normal karyotype. " 09/01/1995 - "We have investigated the compartmentalization of aminopeptidase-N-like activity in various blood fractions obtained from patients with acute lymphoid (ALL) or myeloid (AML) leukemia. " 08/01/1990 - "Patients with CD34+ leukemia were more likely to have blasts expressing CD22, CD9, and CD13 antigens but were less likely to coexpress CD20. "
4.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 06/01/1995 - "Because acute experimental autoimmune encephalomyelitis (EAE) is characterized by a transient and focal perturbation of the BBB, we have utilized the model of adoptive transfer EAE to correlate the expression of the pericytic aminopeptidase N (pAP N) with the acute functional state of the BBB. " 06/01/1995 - "Changes in the expression pattern of blood-brain barrier-associated pericytic aminopeptidase N (pAP N) in the course of acute experimental autoimmune encephalomyelitis." 03/01/2011 - "PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice." 01/01/2009 - "Moreover, these inhibitors are capable of attenuating the severity of autoimmune diseases, such as experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis, and experimental arthritis, a model of human rheumatoid arthritis, in vivo, particularly in combination with inhibitors of aminopeptidase N (APN, CD13) enzymatic activity. "
5.	Colitis 10/01/2007 - "Inhibition of alanyl-aminopeptidase on CD4+CD25+ regulatory T-cells enhances expression of FoxP3 and TGF-beta1 and ameliorates acute colitis in mice."

Related Drugs and Biologics

1.	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)
2.	bestatin (ubenimex)
3.	aminopeptidase B
4.	Peptide Hydrolases (Proteases)
5.	Opioid Peptides (Opioid Peptide)
6.	Transforming Growth Factor beta1 (TGF beta 1)
7.	Tuftsin
8.	Protease Inhibitors (Protease Inhibitor)
9.	Enzymes
10.	Neprilysin (Neutral Endopeptidase)

Related Therapies and Procedures

1.	Adjuvant Chemotherapy
2.	Heterologous Transplantation (Xenotransplantation)
3.	Transplants (Transplant)
4.	Neoadjuvant Therapy
5.	Immunotherapy